Recent

% | $
Quotes you view appear here for quick access.

Apricus Biosciences, Inc. Message Board

  • court.fool2000 court.fool2000 Feb 8, 2013 4:12 PM Flag

    FEMPROX RESULTS FOR FEMALE SEXUAL AROUSAL BY DR. IRWIN GOLDSTEIN

    %
    Primary Efficacy Endpoint: Satisfying Sexual Events(SSEs)
    Balanced baseline scores at screening
    Placebo
    500 mcg 700 mcg 900 mcg Alprostadil Alprostadil Alprostadil
    N 97 91 91 95 Baseline 10.50(20.41) 9.65(17.51) 9.45(18.73) 9.63(16.91)
    n= 97 n= 91 n= 91 n= 95
    4
    
    Secondary Efficacy Endpoint: FSFI
    Secondary Efficacy Endpoint: FSFI
    All ITT Subjects Baseline
    14.85 (4.30) 20.30 (7.01)
    14.02 (3.87) 21.70 (6.84)
    13.90 (4.20) 22.00 (6.25)
    14.65 (3.94) 23.19 (7.26)
    Entire Treatment
    p vs placebo
    0.0652
    0.0360
    0.0018
    Change
    p vs placebo
    5.46 (7.64)
    7.68 (6.68) 0.0747
    8.11 (6.82) 0.0360
    8.55 (7.39) 0.0017
    Placebo (N=97)
    500 mcg (N=91)
    700 mcg (N=91)
    900 mcg (N=95)
    Total FSFI Scores, Mean (SD)
    P values from ANCOVA with treatment and center as fixed factors and baseline as covariate. No correction for multiple comparisons was made.
    5
    Key Overall Efficacy Results (Intent-To-Treat Population)
    • The overall analysis of the primary endpoint show

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
APRI
0.334-0.006(-1.74%)Jul 22 3:57 PMEDT